Home > Gastroenterology > ECCO 2020 > Short- and Long-Term Treatment Results > Tofacitinib ‘real-world’ effectiveness in active UC

Tofacitinib ‘real-world’ effectiveness in active UC

Presented By
Dr M. Chaparro , Hospital Universitario de La Princesa, Spain
Conference
ECCO 2020
Trial
OCTAVE
Tofacitinib is relatively effective in ulcerative colitis (UC) patients in real practice, even in a highly refractory cohort of patients from the prospectively maintained ENEIDA registry [1]. Only 12% of patients not in remission at week 8 reached remission at week 16. Clinical activity and effectiveness were defined in terms of partial Mayo score (PMS). Included were 113 UC patients who were exposed to tofacitinib for a median of 44 weeks. After 8 weeks, response and remission rates were 60% and 31%, respectively; these rates were still similar at week 16 (see Figure). Higher PMS at week 4 (OR 0.2; 95% CI 0.1–0.4) was associated with a reduced odds of achieving remission after 8 weeks. Higher PMS at week 4 (OR 0.5; 95% CI 0.3–0.7) and higher PMS at week 8 (OR 0.2; 95% CI 0.1–0.5) were associated with a lower chance of remission after 16 weeks. Of patients not in remission at week 4 and week 8, 20% and 12% achieved remission after 16 weeks. Noteworthy, 65%...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on